Supplementary Methods, Tables and Figures from Antitumor Activity of the IGF-1/IGF-2–Neutralizing Antibody Xentuzumab (BI 836845) in Combination with Enzalutamide in Prostate Cancer Models

Le résumé fourni par la source

Supplementary Methods. Supplementary Table S1 shows the dates of mycoplasma testing and STR analysis for each cell line; Supplementary Table S2 shows the primary antibodies used for Western blot or Simple Western{trade mark, serif} analysis, and the TaqMan primer and probe sets used for real-time qPCR; Supplementary Table S3 shows the GSEA results of all C2-canonical pathways with false discovery rate < 0.05; Supplementary Fig. S1 shows protein expression of AR, IGF-1R, and PTEN, and the effect of ENZA and XENT, alone or in combination, on IGF-1R and AKT phosphorylation status in prostate cancer cells; Supplementary Fig. S2 shows analysis of PTEN knockdown by qPCR and Western blot; Supplementary Fig. S3 shows the effect of XENT and ENZA, alone or in combination, on transcript and protein levels of AR-regulated and AR-V7 target genes in VCaP cells; Supplementary Fig. S4 shows the effect of XENT and ENZA, alone or in combination, on caspase 3/7 activity and on total protein levels of apoptotic regulators; Supplementary Fig. S5 shows AR-FL and AR-V7 mRNA and protein expression in LuCaP 96CR PDX; Supplementary Fig. S6 shows the paired end, unstranded RNA-Seq profile matching to the PTEN locus in LuCaP 96CR.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.